Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ngm Biopharmaceuticals Inc (NQ: NGM )

3.810 -0.130 (-3.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 350,652
Open 3.940
Bid (Size) 3.810 (1)
Ask (Size) 4.170 (1)
Prev. Close 3.940
Today's Range 3.800 - 4.020
52wk Range 2.920 - 18.25
Shares Outstanding 78,049,340
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
-20.79%
-20.79%
1 Month
-14.38%
-14.38%
3 Month
-26.16%
-26.16%
6 Month
-71.14%
-71.14%
1 Year
-76.60%
-76.60%

More News

Read More
Insiders Buying Charter Communications And 2 Other Stocks
Via Benzinga
$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
$2.6M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire
After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm
Via Benzinga
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire
Moderna To 170? Plus This Analyst Slashes PT On Funko By 50%
Via Benzinga
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
From NGM Biopharmaceuticals, Inc.
Via Globe NewsWire
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
US Stocks Turn Lower; Dow Tumbles Over 100 Points
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Nasdaq Rises Over 100 Points; Crude Oil Up 1.5%
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.